Furthermore, given that the four biomarkers, MDM2, CDK4, CD34, and TLE1, are very helpful in the differential diagnosis of the histological types of sarcomas in clinical work, we analyzed the expression of the four molecules in the three IMSs to identify whether the four molecules also have differential diagnosis value for the immune subtypes of sarcoma. This evidence concerns the gene CDK4 and sarcoma.